Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

Aura Biosciences (NASDAQ:AURA) highlighted progress across its ocular oncology pipeline and provided updates on a parallel ...

Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for ...

After partnering with Depend last year following his bladder cancer surgery, Colorado head coach Deion Sanders brought his ...

Dr. Pooja Ghatalia presents findings from RETAIN-2, a single-arm phase 2 non-randomized trial evaluating a ...

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with ...

Ten years ago, a discussion in Milan set a demanding project in motion. In a meeting between a biologist and a urologist, one ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

Dr Parikh explained that KEYNOTE-B15 (NCT04700124) is evaluating the role of perioperative enfortumab vedotin (Padcev), an ...